Ra Capital Management, L.P. Sells 376,526 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 376,526 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46. Following the transaction, the insider owned 418,813 shares in the company, valued at $297,357.23. This represents a 47.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.

Werewolf Therapeutics Trading Down 7.6%

NASDAQ:HOWL opened at $0.58 on Thursday. The firm has a market capitalization of $28.38 million, a PE ratio of -0.47 and a beta of 0.41. The firm’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $0.83. Werewolf Therapeutics, Inc. has a 1 year low of $0.50 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors have recently modified their holdings of the stock. Regal Investment Advisors LLC raised its stake in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth about $48,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics in the first quarter worth about $79,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the last quarter. 64.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HOWL has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.